CurrentCentenePolicy CP MP.154

Thyroid Hormones and Insulin Testing in Pediatrics

Defines medical necessity and coding implications for thyroid (TSH, T4, T3) and insulin testing in children aged ≥1 and <18, specifically addressing routine testing in otherwise healthy, including obese, pediatric patients for Centene-affiliated health plans.

Policy Summary

PayerCentene

PolicyThyroid Hormones and Insulin Testing in Pediatrics

Policy CodePolicy CP MP.154

Change TypeNo material change

Effective Date

Next Review Date

Key ActionDo not perform routine thyroid hormone or insulin testing for otherwise healthy pediatric patients (age ≥1 and <18), including those who are obese, as these tests are considered not medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥1 and <18age group addressed

multipleCPTs NMN when paired

severaltrigger diagnoses

09/24last revision

Coverage Criteria — Thyroid and Insulin Testing (Pediatrics)

Not medically necessary: Routine testing

Tests are considered not medically necessary in routine screening of otherwise healthy children including those who are obese

Routine thyroid testing NMN: Routine thyroid hormone testing in healthy, including obese but otherwise healthy, children (age ≥ 1 and < 18) is not medically necessary because these tests have not been demonstrated to have a clear clinical benefit.

From policy statement I

Routine insulin testing NMN: Routine insulin testing in healthy, including obese but otherwise healthy, children (age ≥ 1 and < 18) is not medically necessary because these tests have not been demonstrated to have a clear clinical benefit.

From policy statement II

Assessment of thyroid function or insulin may be appropriate when there is clinical suspicion of thyroid disease or glucose dysregulation (for example, symptoms or signs consistent with hypothyroidism, hyperthyroidism, or diabetes). However, this policy specifically addresses routine laboratory screening in otherwise healthy pediatric patients. The background and guideline references emphasize that routine endocrine laboratory evaluation for pediatric obesity is not recommended unless there are additional clinical concerns such as attenuated growth or abnormal height velocity that prompt focused endocrine assessment. Clinical judgment should guide testing when signs, symptoms, or other findings suggest thyroid dysfunction or diabetes rather than routine screening of asymptomatic children.

Policy Summary

PayerCentene

PolicyThyroid Hormones and Insulin Testing in Pediatrics

Policy CodePolicy CP MP.154

Change TypeNo material change

Effective Date

Next Review Date

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coding — CPT and ICD-10 Pairings

CPT codes not medically necessary when billed with corresponding ICD-10 codesCPTNot Covered

83525	Insulin; total
83527	Insulin; free
84436	Thyroxine; total
84439	Thyroxine; free
84478	Thyroid stimulating hormone (TSH)
84479
84480	Triiodothyronine T3; total (TT-3)
84481	Triiodothyronine T3; free
84482	Triiodothyronine T3; reverse

ICD-10 codes that when billed with CPT codes in Table 1 render testing not medically necessaryICD-10

E66.01	Morbid (severe) obesity due to excess calories
E66.09	Other obesity due to excess calories
E66.1	Drug-induced obesity
E66.3	Overweight
E66.8	Other obesity
E66.9	Obesity, unspecified
Z00.00	Encounter for general adult medical examination without abnormal findings
Z00.129	Encounter for routine child health examination without abnormal findings
Z68.52	Body mass index [BMI] pediatric, 5th percentile to less than 85th percentile for age
Z68.53	Body mass index [BMI] pediatric, 85th percentile to less than 95th percentile for age

1–10 of 11

1/2

Provider Actions, Billing, and Denial Risk

Denial Risk

Not medically necessary CPT/ICD-10 pairings

Not medically necessary CPT/ICD-10 pairings: The CPT codes listed in Table 1 (insulin assays and thyroid hormone assays) are designated not medically necessary when billed with the obesity- and routine-exam–related ICD-10-CM codes listed in Table 2. Providers should not expect coverage when these CPT codes are billed in conjunction with those ICD-10-CM codes for otherwise healthy children.

Affected CPTs: 83525, 83527, 84436, 84439, 84478, 84479, 84480, 84481, 84482
Affected ICD-10-CMs: E66.01, E66.09, E66.1, E66.3, E66.8, E66.9, Z00.00, Z00.129, Z00.8, Z68.52, Z68.53, Z68.54

Documentation Required

Claim documentation and coding linkage

Claim documentation and coding linkage: When submitting claims, reference the CPT codes in Table 1 and ensure diagnosis coding accurately reflects clinical indication. If the clinical record supports medical necessity (e.g., clinical signs, abnormal growth/height velocity, or other specific indications), document those findings clearly; routine screening or obesity-related encounter codes alone do not support medical necessity. Claims with CPT codes from Table 1 billed with the ICD-10-CM codes listed in Table 2 are subject to denial.

Document clinical rationale in the medical record (symptoms, abnormal exam findings, growth/height velocity concerns, relevant laboratory abnormalities)
Ensure ICD-10-CM reflects the specific medical indication rather than a routine exam or obesity screening code
Claims with only routine/obesity ICD-10s + listed CPTs may be denied without additional supporting documentation

Step Therapy

Step therapy / sequencing

Step therapy / sequencing: There are no step therapy requirements for thyroid or insulin testing in this policy. However, routine testing in otherwise healthy children (including those who are obese) is considered not medically necessary per guideline recommendations; testing should follow clinical evaluation and guideline-directed indications rather than routine screening sequencing.

No prior step(s) required before ordering tests when clinically indicated
Routine screening tests in healthy pediatric patients (age ≥1 and <18), including for obesity alone, are not supported by this policy and are at risk for denial

Definitions — Test Types

Insulin testing (in pediatric obesity)

DefinitionMeasurement of fasting or non‑fasting plasma insulin concentrations to evaluate insulin resistance in pediatric patients, particularly those with obesity.

Clinical utilityConsidered a research tool with no clinical diagnostic value for evaluating insulin resistance in children because of assay variability, poor reproducibility, and lack of standardized cutoffs.

LimitationsConsiderable overlap exists between insulin concentrations in insulin‑resistant and insulin‑sensitive youths; no well‑defined numeric threshold distinguishes normal from abnormal.

Assay issuesLack of standardized insulin assays, poor reproducibility even within the same assay, and cross‑reactivity with proinsulin limit interpretability.

Clinical recommendationGuidelines recommend against measuring insulin concentrations when evaluating children/adolescents for obesity as it has no diagnostic merit.

Thyroid testing

DefinitionAssays that measure thyroid‑axis hormones including thyroid‑stimulating hormone (TSH), thyroxine (T4, total and free), and triiodothyronine (T3, total and free) to assess thyroid homeostasis.

Physiology noteT4 is the major secreted thyroid hormone and is converted to T3; TSH from the pituitary regulates T4 secretion via the hypothalamic‑pituitary‑thyroid feedback axis.

Role in pediatric obesityTSH and total T4 can be elevated in children who are overweight or obese, but causality is unclear and routine screening may not provide actionable clinical information.

Guideline positionClinical guidelines recommend against routine laboratory evaluation for endocrine causes of pediatric obesity (including routine thyroid testing) unless growth patterns (stature/height velocity) suggest an endocrine disorder.

Background — Physiology and Rationale

Thyroid hormones (TSH, T4, T3) regulate metabolism through the hypothalamic–pituitary–thyroid axis; T4 is the principal secreted hormone and is converted to the active T3. TSH from the pituitary controls thyroid hormone secretion via negative feedback. In pediatrics, mild elevations of TSH and total T4 can be observed in children who are overweight or obese, but current evidence does not clarify whether these abnormalities are a cause or consequence of obesity, and thus routine screening may not yield actionable information. Additionally, measurement of plasma insulin concentrations to evaluate insulin resistance in youth is limited by wide overlap between insulin-resistant and insulin-sensitive individuals, lack of standardized assays, poor reproducibility, and absence of validated numeric cutoffs; consequently insulin measurement remains a research tool rather than a clinically useful screening test in pediatric obesity.

OpenPayer